Indomethacin

Introduction Overview

Generic Name

indomethacin

Brand Name

Indocin, Indocin SR

Dosage Form

oral capsule, oral capsule extended release, oral suspension

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Indomethacin is well absorbed from the gastrointestinal tract after oral administration. Rapid and nearly complete absorption is typical, with peak plasma concentrations usually attained within 1 to 2 hours after taking immediate-release formulations. The extent of absorption can be affected by food intake, with some studies indicating that taking the drug with food or milk may delay absorption but does not significantly affect the total bioavailability. Extended-release formulations release the drug more slowly, achieving a prolonged plasma concentration profile that supports once or twice daily dosing. This modification is critical in sustaining therapeutic levels while potentially reducing gastrointestinal adverse effects.

Distribution:
Indomethacin demonstrates extensive plasma protein binding, primarily to albumin, with greater than 90% bound at therapeutic concentrations. The volume of distribution is moderate, reflecting distribution beyond the plasma compartment into tissues. Indomethacin crosses biological membranes and can enter synovial fluid, which is particularly important for its efficacy in treating arthritic conditions. Penetration into the central nervous system is limited but sufficient to exert some central effects. The high protein binding also implies that indomethacin may compete with other protein-bound drugs, leading to potential drug interactions.

Metabolism:
This drug undergoes hepatic metabolism predominantly via O-demethylation and conjugation pathways, resulting in several inactive metabolites. Cytochrome P450 enzymes, particularly CYP2C9, play a significant role in the biotransformation process. The metabolic clearance is subject to interindividual variability based on hepatic enzyme activity and potential comedications influencing CYP enzymes. Additionally, some conjugated metabolites are pharmacologically inactive but are important for renal excretion processes.

Elimination:
Indomethacin and its metabolites are primarily eliminated via renal excretion, with approximately 60% of the dose recovered in urine. A smaller proportion is excreted in feces, mainly through biliary secretion. The elimination half-life ranges from 4.5 to 6 hours for immediate-release formulations, whereas the extended-release capsules provide a sustained plasma level with longer half-life characteristics yielding prolonged therapeutic exposure. Renal impairment can affect elimination, necessitating dose adjustments and close monitoring. Hepatic dysfunction may also alter metabolism, potentially increasing systemic exposure and risk of toxicity.

Dosage Forms

Available Dosage Forms:
Indomethacin is available in several oral dosage forms to address varying clinical needs:
- Oral capsule immediate release: 25 mg and 50 mg capsules.
- Oral capsule extended release (Indocin SR): 75 mg capsules designed for sustained drug release.
- Oral suspension (liquid): 25 mg/5 mL, suitable for patients having difficulty swallowing capsules or when flexible dosing is required.

Dosages for Adults and Adolescents:
Dosing regimens vary depending on the indication, severity of symptoms, and patient response. Typical adult doses range from 25 mg two to three times daily for immediate-release capsules. Extended-release capsules are usually dosed as 75 mg once or twice daily. The oral suspension dosing is calculated based on mg/kg for pediatric patients older than 14 years, ensuring appropriate therapeutic levels. Total daily doses should be kept at the lowest effective amount to minimize adverse effects.

Specific Patient Populations:
In elderly patients, caution is advised due to increased susceptibility to gastrointestinal toxicity, renal impairment, and cardiovascular risks. Dose adjustments and careful monitoring may be warranted. For patients with renal or hepatic impairment, lower doses and extended dosing intervals may be necessary. The extended-release formulation should not be used in treating gouty arthritis due to insufficient evidence of efficacy in this population. Pediatric use is typically limited to children aged 14 years and older, with dosing adjusted accordingly. Pregnant patients should avoid use in the last 20 weeks of pregnancy due to risks of fetal harm and pregnancy complications.

Mechanism Of Action

Indomethacin functions primarily as a potent nonselective inhibitor of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2 isoforms. These enzymes catalyze the conversion of arachidonic acid to prostaglandin H2, the precursor of various prostanoids including prostaglandins and thromboxanes, which play crucial roles in mediating inflammation, pain, and fever. By inhibiting COX enzymes, indomethacin effectively decreases the synthesis of prostaglandins responsible for sensitizing nerve endings and promoting inflammatory responses.

At the molecular level, indomethacin binds reversibly to the active sites of COX enzymes, blocking substrate access and interrupting prostaglandin biosynthesis. The inhibition of COX-1 is associated with reduced prostaglandin production that normally protects the gastric mucosa and maintains renal blood flow, contributing to the gastrointestinal and renal side effects observed clinically. The COX-2 inhibition is primarily responsible for anti-inflammatory and analgesic effects.

The drug also modulates leukocyte function and decreases migration of immune cells to inflamed tissues, reducing the overall inflammatory milieu. Additionally, some evidence suggests indomethacin may inhibit phospholipase A2 activity and reduce proinflammatory cytokine production, contributing further to its anti-inflammatory properties.

Clinically, indomethacin’s mechanism accounts for its efficacy in treating various inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gouty arthritis, bursitis, and tendonitis. Compared with other NSAIDs, indomethacin exhibits a relatively higher potency in COX inhibition, which correlates with its effectiveness but may also underpin a higher incidence of adverse effects. Research studies have demonstrated that indomethacin’s rapid reduction of prostaglandin levels leads to decreased pain and swelling, validated by randomized controlled trials in arthritic patient populations.

Pharmacological Actions

Nonselective inhibition of cyclooxygenase enzymes leading to decreased prostaglandin synthesis
Anti-inflammatory effects by reducing mediators of inflammation
Analgesic properties through the inhibition of prostaglandin-mediated pain sensitization
Antipyretic effects due to reduction of hypothalamic prostaglandin E2 involved in fever
Inhibition of leukocyte migration and modulation of immune cell activity
Reduction of synovial inflammation and joint swelling in arthritis
Decrease in tendon and bursal inflammation alleviating musculoskeletal pain
Suppresses prostaglandin-induced vasodilation contributing to decreased edema
Potential inhibition of phospholipase A2 and related inflammatory pathways
Transient antiplatelet activity through thromboxane A2 synthesis inhibition
Modulation of central nervous system pain pathways via peripheral COX inhibition
Alleviation of symptoms associated with acute gout attacks
Reduction of stiffness and improved mobility in chronic inflammatory joint diseases
Pharmacokinetic properties allow for both immediate and sustained therapeutic effects
Demonstrated efficacy in multiple inflammatory and rheumatologic conditions

Therapeutic Or Clinical Uses

Treatment of moderate to severe osteoarthritis to reduce pain and inflammation
Management of rheumatoid arthritis symptoms and joint swelling
Therapy for ankylosing spondylitis to improve spinal inflammation and mobility
Acute treatment of gouty arthritis flares to alleviate intense joint pain
Relief of pain and inflammation associated with bursitis
Management of tendonitis-induced shoulder pain
Off-label uses include treatment of certain soft tissue inflammatory conditions
Reduction of fever and pain following musculoskeletal injuries
Adjunctive therapy in symptomatic management of juvenile idiopathic arthritis (in adolescents)
Alternative NSAID choice in patients intolerant to other anti-inflammatory agents
Prevention and treatment of patent ductus arteriosus in neonates (intravenous formulation, not detailed here)
Supportive therapy in various inflammatory conditions requiring short-term NSAIDs
Used when rapid anti-inflammatory effects are desired due to its potency
Employed in clinical settings requiring flexible dosing through oral suspension
Treatment regimens tailored to minimize adverse effects while controlling inflammation

Side Or Adverse Effects

Headache and dizziness as common neurological side effects
Gastrointestinal disturbances including heartburn, stomach pain, and gas
Nausea and vomiting occurring frequently during treatment
Risk of serious gastrointestinal adverse events such as bleeding, ulceration, and perforation
Potential for severe allergic reactions including hives, facial swelling, and breathing difficulties
Serious skin reactions including rash, blistering, and peeling that may necessitate discontinuation
Neuropsychiatric symptoms such as tremors, seizures, confusion, depression, and psychosis
Elevation of blood pressure and associated cardiovascular risks
Kidney toxicity manifesting as fluid retention, reduced urine output, and renal impairment
Liver dysfunction evidenced by loss of appetite, jaundice, dark urine, and elevated liver enzymes
Hematological effects including anemia and unusual bruising or bleeding tendencies
Exacerbation of asthma symptoms or induction of bronchospasm in susceptible individuals
Increased risk of heart attack or stroke, especially with prolonged use or in cardiovascular disease patients
Potential electrolyte imbalance such as hyperkalemia causing cardiac irregularities
Potential CNS side effects including drowsiness and impaired cognitive function

Precautions

Use the lowest effective dose for the shortest duration to minimize risks
Avoid in patients with known hypersensitivity to indomethacin, aspirin, or other NSAIDs
Monitor elderly patients closely due to increased susceptibility to gastrointestinal and renal adverse effects
Use with caution in patients with a history of gastrointestinal ulcers, bleeding, or inflammatory bowel disease
Regular monitoring of renal and liver function during therapy is recommended
Patients with cardiovascular disease or risk factors require careful assessment before use
Avoid use in late stages of pregnancy due to potential fetal harm and pregnancy complications
Caution in patients with asthma due to potential exacerbation of bronchospastic reactions
Avoid concomitant use with other NSAIDs or aspirin unless under direct medical supervision
Inform healthcare providers about all concurrent medications to avoid interactions
Avoid alcohol and smoking which may increase GI bleeding risk
Monitor blood pressure regularly as indomethacin may cause or exacerbate hypertension
Screen for psychiatric symptoms especially if there is a history of neurological disorders
Use caution when performing tasks requiring mental alertness until individual response is known
Adjust dose or discontinue if signs of liver dysfunction or serious side effects emerge

Warnings

Indomethacin increases the risk of fatal heart attack and stroke; avoid use before or after coronary artery bypass graft (CABG) surgery
Serious gastrointestinal bleeding or perforation can occur at any time during therapy without warning
Stop treatment immediately and seek emergency care if symptoms of severe allergic or skin reactions occur
Possible neurological disturbances including seizures and psychosis necessitate vigilance
May worsen preexisting hypertension and congestive heart failure due to fluid retention
Use during pregnancy, particularly after 20 weeks gestation, may cause fetal harm including premature closure of ductus arteriosus
Risk of renal failure in susceptible patients especially with concurrent nephrotoxic drugs
Potential for severe hepatotoxicity requiring regular liver function monitoring
Not recommended for long-term use given cumulative risk of cardiovascular and gastrointestinal adverse events
Use with extreme caution in patients with bleeding disorders or those on anticoagulant therapy
Avoid sudden discontinuation in chronic users without medical consultation
Potential interaction with antidepressants may increase risk of bleeding
Not indicated for use in children under 14 years except under specialist supervision
May mask signs of infection or fever, complicating clinical evaluation
Inform patients about early signs of toxicity including stomach pain, blood in stools, or unusual bruising

Contraindication

Known hypersensitivity to indomethacin or other NSAIDs
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Active or history of recurrent gastrointestinal bleeding or ulcers
Severe renal or hepatic impairment
Established cardiovascular diseases with high risk of thrombotic events
Pregnancy in the third trimester due to fetal risk
Perioperative period of coronary artery bypass graft (CABG) surgery
Bleeding disorders or coagulation defects
Patients with severe uncontrolled hypertension
Concurrent use with other NSAIDs or aspirin for analgesic/anti-inflammatory effects
Known history of severe skin reactions to NSAIDs
Severe dehydration or volume depletion states
Patients with active peptic ulcer disease
Hypersensitivity to any components of the drug formulation
Pediatric patients under 14 years of age without specialist recommendation

Drug Interactions

Concurrent use with anticoagulants such as warfarin increases bleeding risk
Concomitant administration with antiplatelet agents (clopidogrel, ticlopidine) heightens hemorrhagic complications
Coadministration with corticosteroids increases gastrointestinal ulceration risk
Probenecid may reduce renal clearance and increase plasma levels of indomethacin
NSAIDs with selective and nonselective serotonin reuptake inhibitors (SSRIs) may boost bleeding tendency
Other nephrotoxic drugs (aminoglycosides, cyclosporine) combined with indomethacin worsen renal toxicity
Diuretics and antihypertensive drugs may have diminished efficacy due to NSAID-induced sodium retention
Lithium plasma levels can be elevated when combined due to reduced renal clearance
Methotrexate clearance may be impaired, increasing toxicity when taken with indomethacin
Concomitant use with aspirin reduces indomethacin’s effects and increases GI toxicity
Drugs affecting hepatic enzymes (CYP inducers or inhibitors) may alter indomethacin metabolism
Antidepressant agents combined may enhance risk of bleeding and bruising
Alteplase and other fibrinolytics increase risk of bleeding when combined
Interactions with herbal supplements like ginkgo biloba or garlic can increase bleeding risk
Medicines like digoxin may have altered pharmacokinetics due to NSAID-related kidney effects

Preparations Of The Drug

Immediate-release oral capsules in 25 mg and 50 mg strengths
Extended-release oral capsules (Indocin SR) at 75 mg for sustained therapeutic effect
Oral suspension formulation at 25 mg/5 mL concentration for flexible dosing options
Rectal suppositories (available in some markets, not detailed here) for patients unable to tolerate oral route
Intravenous injectable form for specific indications such as patent ductus arteriosus treatment in neonates (professional use)
Combination products not FDA approved in the US should be approached with caution
Available as generic formulations and various branded products including Tivorbex and Indocin
Supplied with measuring devices for suspension to ensure dosing accuracy
Oral extended-release capsules designed to be swallowed whole, not crushed or chewed
Packaging varies by manufacturer, typically in blister packs or bottles for capsules, and bottles for suspensions
Patient information leaflets provided to inform about side effects, storage, and administration
Storage recommended at room temperature away from moisture and heat; suspension must be protected from freezing
Some formulations may contain inactive ingredients to aid absorption and stability
Prescription-only medication requiring healthcare provider oversight for appropriate use
Formulation development aims to balance efficacy and minimize gastrointestinal and systemic toxicity